Latest Extracellular signal-regulated kinases Stories
QUEBEC CITY, Dec. 9, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:Â AEZ) (the "Company") today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131. Data showed that AEZS-131 selectively inhibits Erk at low nanomolar (nM) concentrations and induces G1 arrest. Accordingly, the cytotoxic effect of AEZS-131 was most pronounced in TNBC cell lines with mutations in the...
Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers — combine them with inhibitors of the MEK/ERK signaling pathway. In cases...
An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.As the only cells in the...
QUEBEC CITY, April 5 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:Â AEZ) (the "Company") today announced that a poster on its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131, was presented at the 102(nd) annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida. Poster #3563 Entitled, "A highly selective Erk 1/2 inhibitor with in-vivo anti tumor potency", Irene...
Two enzymes called extracellular signal-regulated kinases (ERK1 and ERK2) are critical factors in a pathway that induces ovulation, maturation of the mammalian egg (oocyte) and other activities key to ovarian function and female fertility, said a group of researchers at Baylor College of Medicine (BCM) in a report that appears today in the journal Science."This finding could provide clues to developing new contraceptives and understanding infertility in some women with irregular...
Ardea Biosciences has announced positive data from a preclinical study of RDEA119, the company's lead mitogen-activated ERK kinase inhibitor, which showed the product candidate to be a promising investigational therapy for inflammatory diseases. According to the company, oral administration of RDEA119 was shown to significantly reduce damage to colonic tissue and disease activity in dextran sulfate sodium - induced chronic colitic mice. The beneficial effect of RDEA119 exceeded that of...
